Tumor boost using external beam radiation in cervical cancer patients unable to receive intracavitary brachytherapy: Outcome from a multicenter retrospective study (Korean Radiation Oncology Group 1419)

Haeyoung Kim, Young Seok Kim, Ji Hyeon Joo, Keun Yong Eom, Won Park, Jin Hee Kim, Jong Hoon Lee, Yeon Sil Kim, Seok Ho Lee, Kijung Ahn, Yongbae Kim, Me Yeon Lee, Sei Kyung Chang

Research output: Contribution to journalArticle

Abstract

Purpose We conducted this study to evaluate the outcomes of external-beam radiotherapy tumor boost (EBRT-B) in cervical cancer patients who could not receive intracavitary brachytherapy. Methods A total of 11 hospitals provided the data of patients who received EBRT-B during the period from January 2005 through October 2012. Results A total of 75 patients were included. The median radiotherapy dose was 46 Gy (range, 40-54 Gy) for whole pelvis and 24 Gy (range, 9-35 Gy) for EBRT-B. Initial tumor responses assessed at 2 to 6 months after radiotherapy were as follows: 46 with complete response, 22 with partial response, 2 with stable disease, and 3 with progressive disease. After a median follow-up time of 33 months, 30 patients (40.0%) showed disease progression including 21 (28.0%) with local progression. The 5-year local failure-free survival rate was 70.0%. Achieving complete response at the first follow-up visit and an overall treatment time of 53 days or less were significantly related to favorable local failure-free survival. The rate of grade 3 or higher toxicity was 2.6%. Conclusions Approximately 70% of patients had local tumor control after curative radiotherapy using EBRT-B. Early tumor response and overall treatment time of 53 days or less were closely associated with favorable local control.

Original languageEnglish
Pages (from-to)371-378
Number of pages8
JournalInternational Journal of Gynecological Cancer
Volume28
Issue number2
DOIs
Publication statusPublished - 2018 Feb 1

Fingerprint

Radiation Oncology
Brachytherapy
Uterine Cervical Neoplasms
Multicenter Studies
Radiotherapy
Retrospective Studies
Radiation
Neoplasms
Pelvis
Disease Progression
Survival Rate
Survival
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Obstetrics and Gynaecology

Cite this

Kim, Haeyoung ; Kim, Young Seok ; Joo, Ji Hyeon ; Eom, Keun Yong ; Park, Won ; Kim, Jin Hee ; Lee, Jong Hoon ; Kim, Yeon Sil ; Lee, Seok Ho ; Ahn, Kijung ; Kim, Yongbae ; Lee, Me Yeon ; Chang, Sei Kyung. / Tumor boost using external beam radiation in cervical cancer patients unable to receive intracavitary brachytherapy : Outcome from a multicenter retrospective study (Korean Radiation Oncology Group 1419). In: International Journal of Gynecological Cancer. 2018 ; Vol. 28, No. 2. pp. 371-378.
@article{616fe01e3eda487896c8bccc7025c41b,
title = "Tumor boost using external beam radiation in cervical cancer patients unable to receive intracavitary brachytherapy: Outcome from a multicenter retrospective study (Korean Radiation Oncology Group 1419)",
abstract = "Purpose We conducted this study to evaluate the outcomes of external-beam radiotherapy tumor boost (EBRT-B) in cervical cancer patients who could not receive intracavitary brachytherapy. Methods A total of 11 hospitals provided the data of patients who received EBRT-B during the period from January 2005 through October 2012. Results A total of 75 patients were included. The median radiotherapy dose was 46 Gy (range, 40-54 Gy) for whole pelvis and 24 Gy (range, 9-35 Gy) for EBRT-B. Initial tumor responses assessed at 2 to 6 months after radiotherapy were as follows: 46 with complete response, 22 with partial response, 2 with stable disease, and 3 with progressive disease. After a median follow-up time of 33 months, 30 patients (40.0{\%}) showed disease progression including 21 (28.0{\%}) with local progression. The 5-year local failure-free survival rate was 70.0{\%}. Achieving complete response at the first follow-up visit and an overall treatment time of 53 days or less were significantly related to favorable local failure-free survival. The rate of grade 3 or higher toxicity was 2.6{\%}. Conclusions Approximately 70{\%} of patients had local tumor control after curative radiotherapy using EBRT-B. Early tumor response and overall treatment time of 53 days or less were closely associated with favorable local control.",
author = "Haeyoung Kim and Kim, {Young Seok} and Joo, {Ji Hyeon} and Eom, {Keun Yong} and Won Park and Kim, {Jin Hee} and Lee, {Jong Hoon} and Kim, {Yeon Sil} and Lee, {Seok Ho} and Kijung Ahn and Yongbae Kim and Lee, {Me Yeon} and Chang, {Sei Kyung}",
year = "2018",
month = "2",
day = "1",
doi = "10.1097/IGC.0000000000001155",
language = "English",
volume = "28",
pages = "371--378",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

Tumor boost using external beam radiation in cervical cancer patients unable to receive intracavitary brachytherapy : Outcome from a multicenter retrospective study (Korean Radiation Oncology Group 1419). / Kim, Haeyoung; Kim, Young Seok; Joo, Ji Hyeon; Eom, Keun Yong; Park, Won; Kim, Jin Hee; Lee, Jong Hoon; Kim, Yeon Sil; Lee, Seok Ho; Ahn, Kijung; Kim, Yongbae; Lee, Me Yeon; Chang, Sei Kyung.

In: International Journal of Gynecological Cancer, Vol. 28, No. 2, 01.02.2018, p. 371-378.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Tumor boost using external beam radiation in cervical cancer patients unable to receive intracavitary brachytherapy

T2 - Outcome from a multicenter retrospective study (Korean Radiation Oncology Group 1419)

AU - Kim, Haeyoung

AU - Kim, Young Seok

AU - Joo, Ji Hyeon

AU - Eom, Keun Yong

AU - Park, Won

AU - Kim, Jin Hee

AU - Lee, Jong Hoon

AU - Kim, Yeon Sil

AU - Lee, Seok Ho

AU - Ahn, Kijung

AU - Kim, Yongbae

AU - Lee, Me Yeon

AU - Chang, Sei Kyung

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Purpose We conducted this study to evaluate the outcomes of external-beam radiotherapy tumor boost (EBRT-B) in cervical cancer patients who could not receive intracavitary brachytherapy. Methods A total of 11 hospitals provided the data of patients who received EBRT-B during the period from January 2005 through October 2012. Results A total of 75 patients were included. The median radiotherapy dose was 46 Gy (range, 40-54 Gy) for whole pelvis and 24 Gy (range, 9-35 Gy) for EBRT-B. Initial tumor responses assessed at 2 to 6 months after radiotherapy were as follows: 46 with complete response, 22 with partial response, 2 with stable disease, and 3 with progressive disease. After a median follow-up time of 33 months, 30 patients (40.0%) showed disease progression including 21 (28.0%) with local progression. The 5-year local failure-free survival rate was 70.0%. Achieving complete response at the first follow-up visit and an overall treatment time of 53 days or less were significantly related to favorable local failure-free survival. The rate of grade 3 or higher toxicity was 2.6%. Conclusions Approximately 70% of patients had local tumor control after curative radiotherapy using EBRT-B. Early tumor response and overall treatment time of 53 days or less were closely associated with favorable local control.

AB - Purpose We conducted this study to evaluate the outcomes of external-beam radiotherapy tumor boost (EBRT-B) in cervical cancer patients who could not receive intracavitary brachytherapy. Methods A total of 11 hospitals provided the data of patients who received EBRT-B during the period from January 2005 through October 2012. Results A total of 75 patients were included. The median radiotherapy dose was 46 Gy (range, 40-54 Gy) for whole pelvis and 24 Gy (range, 9-35 Gy) for EBRT-B. Initial tumor responses assessed at 2 to 6 months after radiotherapy were as follows: 46 with complete response, 22 with partial response, 2 with stable disease, and 3 with progressive disease. After a median follow-up time of 33 months, 30 patients (40.0%) showed disease progression including 21 (28.0%) with local progression. The 5-year local failure-free survival rate was 70.0%. Achieving complete response at the first follow-up visit and an overall treatment time of 53 days or less were significantly related to favorable local failure-free survival. The rate of grade 3 or higher toxicity was 2.6%. Conclusions Approximately 70% of patients had local tumor control after curative radiotherapy using EBRT-B. Early tumor response and overall treatment time of 53 days or less were closely associated with favorable local control.

UR - http://www.scopus.com/inward/record.url?scp=85041453596&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041453596&partnerID=8YFLogxK

U2 - 10.1097/IGC.0000000000001155

DO - 10.1097/IGC.0000000000001155

M3 - Article

C2 - 29189448

AN - SCOPUS:85041453596

VL - 28

SP - 371

EP - 378

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 2

ER -